Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{7e591a5c8eaa446482921bcca8758203,
title = "Tuberculosis case finding and mortality prediction: added value of the clinical TBscore and biomarker suPAR",
abstract = "SETTING: A suburban area of Bissau, the capital of Guinea-Bissau; the study was conducted among presumptive pulmonary tuberculosis (prePTB) patients seeking medical care for signs and symptoms suggestive of PTB.OBJECTIVE: To determine if a clinical TB score and a biomarker suPAR (soluble urokinase plasminogen activator receptor) have separate and composite ability to predict PTB diagnosis and mortality in prePTB patients.DESIGN: Observational prospective follow-up study conducted from August 2010 to August 2012.RESULTS: We included 1011 prePTB patients (mean age 34 years, 95{\%}CI 33-35); 55{\%} (n = 559) were female and 161 (16{\%}) had human immunodeficiency virus (HIV) infection. Of all included patients, 10{\%} (n = 101) were diagnosed with PTB. Mortality during follow-up was 5{\%} (n = 48), with a mean survival time of 158 days (95{\%}CI 27-289) in prePTB patients diagnosed with PTB vs. 144 days (95{\%}CI 109-178) in those not diagnosed with PTB (P = 0.774). After adjusting for HIV status and age, the best separate predictor was suPAR 5 ng/ml, with a hazard ratio (HR) of 4.6 (95{\%}CI 2.1-9.9) for mortality and 6.7 (95{\%}CI 4.0-11.2) for TB diagnosis. All patients who died had a TBscore II + suPAR 7; the HR of the composite score for subsequent PTB diagnosis was 33.0 (95{\%}CI 4.6-236.6).CONCLUSION: The proposed composite score of suPAR + TBscore II 7 can improve TB case finding and clinical monitoring.",
author = "F Rudolf and A-J Wagner and Back, {F M} and Gomes, {V F} and P Aaby and L {\O}stergaard and J Eugen-Olsen and C Wejse",
year = "2017",
month = "1",
day = "1",
doi = "10.5588/ijtld.16.0404",
language = "English",
volume = "21",
pages = "67--72",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tuberculosis and Lung Disease (I U A T L D)",
number = "1",

}

RIS

TY - JOUR

T1 - Tuberculosis case finding and mortality prediction

T2 - added value of the clinical TBscore and biomarker suPAR

AU - Rudolf, F

AU - Wagner, A-J

AU - Back, F M

AU - Gomes, V F

AU - Aaby, P

AU - Østergaard, L

AU - Eugen-Olsen, J

AU - Wejse, C

PY - 2017/1/1

Y1 - 2017/1/1

N2 - SETTING: A suburban area of Bissau, the capital of Guinea-Bissau; the study was conducted among presumptive pulmonary tuberculosis (prePTB) patients seeking medical care for signs and symptoms suggestive of PTB.OBJECTIVE: To determine if a clinical TB score and a biomarker suPAR (soluble urokinase plasminogen activator receptor) have separate and composite ability to predict PTB diagnosis and mortality in prePTB patients.DESIGN: Observational prospective follow-up study conducted from August 2010 to August 2012.RESULTS: We included 1011 prePTB patients (mean age 34 years, 95%CI 33-35); 55% (n = 559) were female and 161 (16%) had human immunodeficiency virus (HIV) infection. Of all included patients, 10% (n = 101) were diagnosed with PTB. Mortality during follow-up was 5% (n = 48), with a mean survival time of 158 days (95%CI 27-289) in prePTB patients diagnosed with PTB vs. 144 days (95%CI 109-178) in those not diagnosed with PTB (P = 0.774). After adjusting for HIV status and age, the best separate predictor was suPAR 5 ng/ml, with a hazard ratio (HR) of 4.6 (95%CI 2.1-9.9) for mortality and 6.7 (95%CI 4.0-11.2) for TB diagnosis. All patients who died had a TBscore II + suPAR 7; the HR of the composite score for subsequent PTB diagnosis was 33.0 (95%CI 4.6-236.6).CONCLUSION: The proposed composite score of suPAR + TBscore II 7 can improve TB case finding and clinical monitoring.

AB - SETTING: A suburban area of Bissau, the capital of Guinea-Bissau; the study was conducted among presumptive pulmonary tuberculosis (prePTB) patients seeking medical care for signs and symptoms suggestive of PTB.OBJECTIVE: To determine if a clinical TB score and a biomarker suPAR (soluble urokinase plasminogen activator receptor) have separate and composite ability to predict PTB diagnosis and mortality in prePTB patients.DESIGN: Observational prospective follow-up study conducted from August 2010 to August 2012.RESULTS: We included 1011 prePTB patients (mean age 34 years, 95%CI 33-35); 55% (n = 559) were female and 161 (16%) had human immunodeficiency virus (HIV) infection. Of all included patients, 10% (n = 101) were diagnosed with PTB. Mortality during follow-up was 5% (n = 48), with a mean survival time of 158 days (95%CI 27-289) in prePTB patients diagnosed with PTB vs. 144 days (95%CI 109-178) in those not diagnosed with PTB (P = 0.774). After adjusting for HIV status and age, the best separate predictor was suPAR 5 ng/ml, with a hazard ratio (HR) of 4.6 (95%CI 2.1-9.9) for mortality and 6.7 (95%CI 4.0-11.2) for TB diagnosis. All patients who died had a TBscore II + suPAR 7; the HR of the composite score for subsequent PTB diagnosis was 33.0 (95%CI 4.6-236.6).CONCLUSION: The proposed composite score of suPAR + TBscore II 7 can improve TB case finding and clinical monitoring.

U2 - 10.5588/ijtld.16.0404

DO - 10.5588/ijtld.16.0404

M3 - Journal article

VL - 21

SP - 67

EP - 72

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 1

ER -

ID: 49798164